hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma TherapyEran Elyakim, Noga Yerushalmi, Dalia Cohen et al.|Cancer Research|2010Cited by 152
Supplementary Figures 1-9, Table 1 from hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma TherapyEran Elyakim, Noga Yerushalmi, Einat Sitbon et al.|Unknown|2023Cited by 0
Supplementary Figures 1-9, Table 1 from hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma TherapyEran Elyakim, Noga Yerushalmi, Einat Sitbon et al.|Unknown|2023Cited by 0
Data from hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma TherapyEran Elyakim, Noga Yerushalmi, Einat Sitbon et al.|Unknown|2023Cited by 0
Data from hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma TherapyEran Elyakim, Noga Yerushalmi, Einat Sitbon et al.|Unknown|2023Cited by 0